Objective:

To investigate the incidence of de novo inflammatory bowel disease (IBD) after metabolic bariatric surgery (MBS) in patients with severe obesity and compare disease severity, measured through medication use and hospitalizations, to matched controls without MBS.

Key Findings:

• Patients undergoing MBS had a higher incidence of de novo IBD compared to matched controls, suggesting a need for monitoring.
• Severity of IBD was assessed through medication use, surgeries, and hospitalizations, indicating a potentially less severe disease course post-MBS, which may influence treatment strategies.

Interpretation:

The findings suggest that while MBS may increase the risk of developing IBD, the disease course may be less severe in these patients compared to those with severe obesity who did not undergo surgery, highlighting the need for tailored management.

Limitations:

• The study is based on claims data, which may not capture all clinical nuances, such as symptom severity or patient-reported outcomes.
• Exclusion criteria may limit generalizability to broader populations, particularly those with different comorbidities or demographics.

Conclusion:

MBS is associated with an increased incidence of de novo IBD in obese adults, but these patients may experience a less severe disease course.